Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Sanofi ADR (NASDAQ: SNY) closed at $49.77 in the last session, up 1.49% from day before closing price of $49.04. In other words, the price has increased by $1.49 from its previous closing price. On the day, 2.02 million shares were traded. SNY stock price reached its highest trading level at $50.04 during the session, while it also had its lowest trading level at $49.4812.
Ratios:
We take a closer look at SNY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.23. For the most recent quarter (mrq), Quick Ratio is recorded 0.94 and its Current Ratio is at 1.27. In the meantime, Its Debt-to-Equity ratio is 0.32 whereas as Long-Term Debt/Eq ratio is at 0.21.
On April 15, 2025, Exane BNP Paribas started tracking the stock assigning a Outperform rating and target price of $65.
On March 21, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $65.Goldman initiated its Neutral rating on March 21, 2025, with a $65 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNY now has a Market Capitalization of 121387048960 and an Enterprise Value of 67771883520. As of this moment, Sanofi’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.43, and their Forward P/E ratio for the next fiscal year is 10.09. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.00. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.80 while its Price-to-Book (P/B) ratio in mrq is 1.47. Its current Enterprise Value per Revenue stands at 1.482 whereas that against EBITDA is 5.609.
Stock Price History:
The Beta on a monthly basis for SNY is 0.50, which has changed by -0.08712399 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, SNY has reached a high of $60.12, while it has fallen to a 52-week low of $44.73. The 50-Day Moving Average of the stock is 2.35%, while the 200-Day Moving Average is calculated to be -2.70%.
Shares Statistics:
According to the various share statistics, SNY traded on average about 2.28M shares per day over the past 3-months and 2667950 shares per day over the past 10 days. A total of 2.61B shares are outstanding, with a floating share count of 2.43B. Insiders hold about 0.00% of the company’s shares, while institutions hold 10.26% stake in the company. Shares short for SNY as of 1753920000 were 3266430 with a Short Ratio of 1.43, compared to 1751241600 on 4392782. Therefore, it implies a Short% of Shares Outstanding of 3266430 and a Short% of Float of 0.15.
Dividends & Splits
The forward annual dividend rate for SNY is 2.21, which was 3.92 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.079934746The stock’s 5-year Average Dividend Yield is 3.78.
Earnings Estimates
Its stock is currently analyzed by 2.0 different market analysts. The consensus estimate for the next quarter is $1.01, with high estimates of $1.01 and low estimates of $1.01.
Analysts are recommending an EPS of between $4.64 and $4.48 for the fiscal current year, implying an average EPS of $4.56. EPS for the following year is $5.05, with 7.0 analysts recommending between $5.21 and $4.86.
Revenue Estimates
According to 5 analysts, the current quarter’s revenue is expected to be $12.63B. It ranges from a high estimate of $13.33B to a low estimate of $12.21B. As of the current estimate, Sanofi ADR’s year-ago sales were $13.44BFor the next quarter, 5 analysts are estimating revenue of $11.3B. There is a high estimate of $12.08B for the next quarter, whereas the lowest estimate is $10.82B.
A total of 13 analysts have provided revenue estimates for SNY’s current fiscal year. The highest revenue estimate was $46.75B, while the lowest revenue estimate was $42.99B, resulting in an average revenue estimate of $44.38B. In the same quarter a year ago, actual revenue was $41.08BBased on 11 analysts’ estimates, the company’s revenue will be $47.35B in the next fiscal year. The high estimate is $49.99B and the low estimate is $45.87B.
